ArticleTargeted oncology2023

Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Margherita Rimini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.